Table 2 Metabolic reprogramming in immunotherapy clinical trials
From: Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
Medications | Target | Combination Therapy | Context | identifier/reference |
|---|---|---|---|---|
Metformin | AMPK | Nivolumab (anti-PD1) | NSCLC | NCT03048500 |
epacadostat | IDO | Pembrolizumab | NSCLC | Keynote-037 |
epacadostat | IDO | Pembrolizumab + Platinum doublet | NSCLC | NCT03322566 |
epacadostat | IDO | Pembrolizumab | NSCLC | NCT03322540 |
IO102 | IDO | Pembrolizumab ± Platinum doublet | NSCLC | NCT T03562871 |
ID05-peptide IDO | IDO | vaccine-based | NSCLC | NCT01219348 |
Telaglenestat (CB-839) | Glutaminase1 inhibitor | Nivolumab | NSCLC | NCT02771626 |
(CB-839) | Glutaminase | pembrolizumab | NSCLC | NCT04265534 |